Levothyroxine Sodium

Levothyroxine Sodium is used to treat goiter, myxedema, thyroid neoplasms, autoimmune thyroiditis and thyrotoxicosis, per the National Library of Medicine's MED-RT classification. The brand product was first FDA-approved on Aug 21, 2000, and the first generic was approved Jun 5, 2002. FDA's Orange Book lists 155 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $843 million on Levothyroxine Sodium across 48.7 million claims for 10.2 million beneficiaries.

Levothyroxine Sodium is available as 416 NDCs from 22 manufacturers (309 generic, 107 brand), with NADAC prices from $0.04 to $4.56 per EA — the most expensive product costs about 130× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.